Autopsy report · NCT05063123

Study to Assess an Interphase Cycle With Flotetuzumab.

“Withdrawal of MacroGenics (pharmaceutical company)”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Stichting Hemato-Oncologie voor Volwassenen Nederland

Sponsor type

University, hospital or other

Conditions

AML

Interventions

Flotetuzumab

Participants

0

Sites

4

Countries

Netherlands

Trials that died the same way

• MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
  “Product withdrawn from clinical development” (67% match in meaning)
• Beta Cell Rescue in New Onset Type 1 Diabetes With Efalizumab
  “drug withdrawn from market” (65% match in meaning)
• 2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML
  “Pharmaceutical Company withdrew support and investigational product” (61% match in meaning)
• The Sub-Sero Study
  “Drug supply withdrawn (dec 2019)” (59% match in meaning)
• Phase 3 Trial to Evaluate the Efficacy and Safety of DKP21102_B Added on to DKP21102_A Compared With DKP21102_A
  “The clinical trial was withdrawn due to a commercial decision.” (59% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.